Magainin
Magainins are 23-amino acid alpha-helical antimicrobial peptides discovered in the skin of the African clawed frog (Xenopus laevis) by Michael Zasloff in 1987, notable for their membrane-disrupting toroidal pore mechanism and cancer cell selectivity.
Magainins (magainin 1 and magainin 2) are 23-amino acid cationic antimicrobial peptides originally isolated from the skin of the African clawed frog Xenopus laevis by Michael Zasloff in 1987. Their discovery — prompted by Zasloff's observation that surgically wounded frogs healed without infection in non-sterile aquarium water — was a seminal moment in antimicrobial peptide research and catalyzed the modern field of host defense peptide biology.
Overview
The name "magainin" derives from the Hebrew word magain (מגן), meaning "shield." Zasloff's 1987 paper in Proceedings of the National Academy of Sciences described the isolation of two related peptides — magainin 1 and magainin 2 — from X. laevis skin gland secretions, demonstrating broad-spectrum antimicrobial activity against bacteria, fungi, and protozoa Zasloff (1987).
Magainin 2 is the more extensively studied and more potent of the two peptides. It adopts a random coil conformation in aqueous solution but transitions to an amphipathic alpha-helix upon binding to lipid membranes — a structural transition essential for its antimicrobial mechanism. The peptide's selectivity for microbial over mammalian membranes arises from preferential interaction with anionic phospholipids abundant in bacterial membranes, while cholesterol-rich, zwitterionic mammalian membranes are relatively resistant.
Magainins have served as one of the most important model systems for understanding antimicrobial peptide mechanisms, particularly the toroidal pore model of membrane disruption. They have also been the basis for extensive structure-activity relationship studies and the development of synthetic analogs with improved therapeutic properties.
Mechanism of Action
Magainins kill microorganisms through the toroidal pore model of membrane disruption:
- Electrostatic attraction: The cationic magainin peptide (+3 to +4 charge) is electrostatically attracted to anionic microbial membrane surfaces. Magainin 2 binds preferentially to membranes containing phosphatidylglycerol (PG) and phosphatidylserine (PS) over phosphatidylcholine (PC) and cholesterol-containing membranes Matsuzaki et al. (1995).
- Helix formation on membrane surface: Upon binding, magainin transitions from a random coil to an amphipathic alpha-helix and initially lies parallel to the membrane surface, inserting into the headgroup region.
- Toroidal pore formation: At a critical peptide-to-lipid ratio (~1:30 for magainin 2), the peptides and lipid headgroups together form a toroidal pore in which the pore lining consists of both peptide molecules and lipid headgroups, curved inward to form a continuous surface. This distinguishes the toroidal model from the barrel-stave model (used by protegrins) where only peptide lines the pore Matsuzaki et al. (1996).
- Membrane permeabilization: The toroidal pores allow leakage of ions, ATP, and small molecules, causing membrane depolarization and cell death. Pores are transient — they form, allow leakage, and collapse, with magainin molecules redistributing to the inner leaflet of the bilayer.
- Cancer cell selectivity: Cancer cells frequently display increased phosphatidylserine (PS) on their outer membrane leaflet (normally confined to the inner leaflet in healthy cells), providing a basis for magainin's preferential activity against cancer cells over normal mammalian cells Cruciani et al. (1991).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Discovery and Characterization
Zasloff's 1987 discovery of magainins was one of the landmark events in antimicrobial peptide research. His observation that surgical wounds on X. laevis frogs healed without infection in bacterially contaminated aquarium water led to the isolation and characterization of magainin 1 and 2 from skin gland secretions. Both peptides exhibited broad-spectrum activity against gram-positive and gram-negative bacteria, fungi (Candida albicans), and protozoa (Amoeba proteus, Paramecium caudatum) at micromolar concentrations Zasloff (1987).
Cancer Cell Selectivity
Magainin 2 and its analogs show preferential cytotoxicity toward cancer cells over normal cells. Cruciani et al. demonstrated that magainin 2 analogs (e.g., magainin A and G) kill human hematopoietic tumor cell lines (HL60, U937, K562) at concentrations that spare normal human erythrocytes and fibroblasts. The selectivity is attributed to increased PS exposure and higher overall anionic charge density on cancer cell surfaces Cruciani et al. (1991). Lehmann et al. further showed activity against bladder cancer cells both in vitro and in xenograft models Lehmann et al. (2006).
Synthetic Analogs and Structure-Activity Relationships
Magainins have been the subject of extensive structure-activity relationship (SAR) studies. Key findings include: increasing cationicity improves antimicrobial potency but also increases hemolytic toxicity; maintaining the amphipathic helix angle is critical for activity; C-terminal amidation improves potency; and dimerization (MSI-594, a tandem magainin-melittin hybrid) can improve activity Maloy & Kari (1995).
Toroidal Pore Model
Magainin 2 has been the principal model peptide for elucidating the toroidal pore mechanism. Matsuzaki et al. provided key evidence through lipid flip-flop assays, vesicle leakage studies, and oriented circular dichroism, showing that magainin induces coupled pore formation and lipid translocation — a hallmark of the toroidal model. The pore diameter was estimated at approximately 2–3 nm, large enough for small molecule leakage but insufficient for macromolecular transport Matsuzaki et al. (1996).
Pexiganan (MSI-78) Clinical Trials
Pexiganan (MSI-78), a synthetic 22-amino acid analog of magainin 2 with enhanced antimicrobial potency, was developed by Magainin Pharmaceuticals (later Genaera Corporation) as a topical antibiotic for infected diabetic foot ulcers.
- Phase III trials (1999): Two large randomized controlled trials compared pexiganan cream (1% and 2%) to oral ofloxacin for treatment of mildly infected diabetic foot ulcers. Pexiganan demonstrated clinical cure rates comparable to ofloxacin (approximately 90%) but the FDA declined approval, citing lack of demonstrated superiority over existing therapies Lipsky et al. (2008).
- Second Phase III attempt (2015–2017): Dipexium Pharmaceuticals conducted additional Phase III trials (APEX trial) of pexiganan cream for mild diabetic foot infections. The trial again failed to demonstrate superiority over the vehicle control, and the development program was discontinued.
- Legacy: Despite commercial failure, pexiganan remains one of the best-studied antimicrobial peptides in clinical development and has contributed valuable data on the feasibility of topical antimicrobial peptide therapeutics.
Safety Profile
Magainins and their analogs exhibit a generally favorable safety profile due to membrane selectivity:
- Low hemolytic activity: Magainin 2 shows minimal hemolytic activity at antimicrobial concentrations, with HC₅₀ values typically >200 μg/mL — an order of magnitude above MIC values. This wide therapeutic index is a key advantage over more hydrophobic antimicrobial peptides like protegrins.
- Topical tolerability: Pexiganan cream was well-tolerated in Phase III clinical trials, with local adverse effects (application site reactions) being mild and comparable to vehicle control.
- Salt sensitivity: Like many cationic antimicrobial peptides, magainin activity is reduced at physiological salt concentrations (150 mM NaCl), which may limit efficacy in certain physiological environments.
- Selectivity basis: The preferential activity against microbial and cancer cells over normal mammalian cells is based on membrane composition differences (anionic vs. zwitterionic lipids, cholesterol content), providing an inherent safety margin.
- No systemic toxicity data: As pexiganan was developed exclusively for topical application, systemic toxicity data in humans are limited.
Pharmacokinetic Profile
Research Protocols
oral
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Low hemolytic activity | 200 μg | Per protocol | — |
topical
Pexiganan (MSI-78) Clinical Trials Pexiganan (MSI-78), a synthetic 22-amino acid analog of magainin 2 with enhanced antimicrobial potency, was developed by Magainin Pharmaceuticals (later Genaera Corporation) as a topical antibiotic for infected diabetic foot ulcers. - Legacy: Despite commercial fa
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 200 μg | Per protocol | — |
Interactions
Peptide Interactions
Magainin disrupts bacterial membranes through pore formation, increasing cell permeability. This facilitates intracellular access for beta-lactam antibiotics that target cell wall synthesis. In vitro studies have demonstrated synergistic bactericidal activity against both Gram-positive and Gram-negative species. (Westerhoff et al., 1995, Proc Natl Acad Sci)
Quality Indicators
What to look for
- Phase 3 clinical trial data available
- Human clinical trials conducted
- Well-established safety profile
- Extensive peer-reviewed research base
Frequently Asked Questions
References (12)
- [9]Aisenbrey C, Marquette A, Bechinger B — The mechanisms of action of cationic antimicrobial peptides refined by novel concepts from biophysical investigations Adv Exp Med Biol (2023)
- [11]Sierra JM et al — Magainin-derived peptides with enhanced stability and selectivity for antibiotic-resistant pathogens Pharmaceutics (2024)
- [1]Zasloff M Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor Proc Natl Acad Sci USA (1987)
- [2]Matsuzaki K, Sugishita K, Fujii N, Miyajima K Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2 Biochemistry (1995)
- [3]Matsuzaki K, Murase O, Fujii N, Miyajima K An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation Biochemistry (1996)
- [4]Cruciani RA, Barker JL, Zasloff M, et al Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation Proc Natl Acad Sci USA (1991)
- [5]Lipsky BA, Holroyd KJ, Zasloff M Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream Clin Infect Dis (2008)
- [6]Lehmann J, Retz M, Sidhu SS, et al Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines Eur Urol (2006)
- [7]Maloy WL, Kari UP Structure-activity studies on magainins and other host defense peptides Biopolymers (1995)
- [8]Bechinger B, Zasloff M, Opella SJ Structure and orientation of the antibiotic peptide magainin in membranes by solid-state nuclear magnetic resonance spectroscopy Protein Sci (1993)
- [10]Mwangi J et al — Antimicrobial peptides: new hope in the war against multidrug resistance Zool Res (2023)
- [12]Dijksteel GS et al — Review: Lessons learned from clinical trials using antimicrobial peptides Front Immunol (2022)
LL-37
LL-37 is the only human cathelicidin antimicrobial peptide, playing a critical role in innate immunity through direct antimicrobial activity, immunomodulation, wound healing, and anti-biofilm properties.
Maritide (AMG 133)
Maritide (AMG 133/MariTide) is a first-in-class bispecific antibody-peptide conjugate that simultaneously activates GLP-1 receptors and antagonizes GIP receptors, developed by Amgen for obesity and metabolic disease with monthly or less frequent dosing.